Abstract
The global literature presents heterogeneous data on the prevalence of meningiomas among intracranial neoplasms. A number of studies indicate that the most common intracranial tumours are meningiomas, gliomas, or metastatic brain lesions. This paper presents the experience of the institution in the treatment of patients with intracranial neoplasms and a comparison of the results obtained with the data published in the literature. The purpose of the study was to evaluate the relative incidence of intracranial meningiomas among all intracranial neoplasms in the Kyrgyz Republic. A retrospective analysis was conducted of 151 consecutive patients treated at the Neurosurgery Clinic of the National Hospital of the Ministry of Health of the Kyrgyz Republic over a 12-month period. All patients underwent neurosurgical intervention, and all tumour samples taken during surgery were subjected to histological examination for a final diagnosis. The study included patients with histologically verified intracranial neoplasms. The authors presented their own experience of diagnosis, treatment, and outcome analysis in patients with meningiomas. In addition, postoperative morbidity and mortality, and the frequency of relapses, were assessed. Given the predominantly benign histological nature of meningiomas, the success of treatment was largely determined by the specific features of the course of the postoperative period. Significant importance was attached to adequate postoperative follow-up of patients. The most frequently identified histological types of tumours were meningiomas, gliomas, and pituitary tumours. During the follow-up period, intracranial meningiomas were histologically confirmed in 48 patients (31.8%), pituitary adenomas in 35 (23.2%), and gliomas in 32 (21.2%). The average age of the patients was 43 years, the ratio of women to men was 1.3:1. The highest frequency of referrals occurred in the fifth (27.1%) and sixth (26.5%) decades of life. The maximum age range was in the age groups of 41-50 years and 51-60 years, which accounted for 27.1% and 26.5% of patients and corresponded to the fifth and sixth decades of life, respectively. With age, women account for a higher prevalence of brain tumours, while men account for a higher prevalence in childhood and younger age. The results indicate that meningioma is the most common type of tumour among intracranial neoplasms in the Kyrgyz Republic
Keywords
meningioma; intracranial neoplasm; prevalence; epidemiologySuggested citation
References
- Bondy M, Ligon BL. Epidemiology and etiology of intracranial meningiomas: A review. J Neurooncol. 1996;29(3):197–205. DOI: 10.1007/BF00165649
- Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109. DOI: 10.1007/s00401-007-0243-4
- Yrysov KB, Arstanbekov NA, Mamytov MM, Akmataliev A, Turganbaev B, Vityala Y. Postoperative complications in patients with intracranial meningiomas who underwent surgery. Biomedicine. 2023;43(3):1023–6. DOI: 10.51248/.v43i3.2886
- Mirimanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, Martuza RL. Meningioma: Analysis of recurrence and progression following neurosurgical resection. J Neurosurg. 1985;62(1):18–24. DOI: 10.3171/ jns.1985.62.1.0018
- Marks SM, Whitwell HL, Lye RH. Recurrence of meningiomas after operation. Surg Neurol. 1986;25(5):436–40. DOI: 10.1016/0090-3019(86)90081-9
- Lemée JM, Corniola MV, Meling TR. Benefits of re-do surgery for recurrent intracranial meningiomas. Sci Rep. 2020;10(1):303. DOI: 10.1038/s41598-019-57254-5
- Leistner T, Terrapon APR, Hostettler IC, Bozinov O, Zeitlberger AM, Neidert MC. Adverse events in meningioma surgery classified using the therapy-disability-neurology (TDN) grading system. J Neurooncol. 2025;176(2):125. DOI: 10.1007/s11060-025-05312-6
- Corell A, Thurin E, Skoglund T, Farahmand D, Henriksson R, Rydenhag B, Gulati S, et al. Neurosurgical treatment and outcome patterns of meningioma in Sweden: A nationwide registry-based study. Acta Neurochir. 2019;161(2):333–41. DOI: 10.1007/s00701-019-03799-3
- Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(5):1–100. DOI: 10.1093/neuonc/noz150
- Duba M, Mrlian A, Rošková I, Smrčka M, Fadrus P, Duba J, et al. Neurosurgical treatment and outcome patterns in patients with meningioma in South Moravian region – a population-based study. Neurol Sci. 2024;45(5):2311–9. DOI: 10.1007/s10072-023-07244-3
- Oya S, Ikawa F, Ichihara N, Wanibuchi M, Akiyama Y, Nakatomi H, et al. Nation-wide brain tumor registry-based study of intracranial meningioma in Japan: Analysis of surgery-related risks. Neurol Med Chir. 2021;61(2):98– 106. DOI: 10.2176/nmc.oa.2020-0304
- Lin MC, Li CZ, Hsieh CC, Hong KY, Lin BJ, Lin C, et al. Preoperative grading of intracranial meningioma by magnetic resonance spectroscopy (1H-MRS). PLoS One. 2018;13(11):e0207612. DOI: 10.1371/journal. pone.0207612
- Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn’t. BMJ. 1996;312(7023):71–2. DOI: 10.1136/bmj.312.7023.71
- Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Intermediate-risk meningioma: Initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018;129(1):35–47. DOI: 10.3171/2016.11. JNS161170
- Scheichel F, Popadic B, Kitzwoegerer M, Ungersboeck K, Marhold F. Fluorescence-guided resection in bone and soft tissue infiltrating meningiomas. Acta Neurochir. 2020;162(3):605–11. DOI: 10.1007/s00701-019-04179-7
- Wadiura LI, Millesi M, Makolli J, Wais J, Kiesel B, Mischkulnig M, et al. High diagnostic accuracy of visible 5-ALA fluorescence in meningioma surgery according to histopathological analysis of tumor bulk and peritumoral tissue. Lasers Surg Med. 2021;53(3):300–8. DOI: 10.1002/lsm.23294
- Dincer A, Morales-Valero SF, Robert SM, Tabor JK, O’Brien J, Yalcin K, et al. Surgical strategies for intracranial meningioma in the molecular era. J Neurooncol. 2023;162(2):253–65. DOI: 10.1007/s11060-023-04272-z
- Brastianos PK, Galanis E, Butowski N, Chan JW, Dunn IF, Goldbrunner R, et al. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019;21(1):18–31. DOI: 10.1093/neuonc/noy136
- Gousias K, Schramm J, Simon M. The Simpson grading revisited: Aggressive surgery and its place in modern meningioma management. J Neurosurg. 2016;125(3):551–60. DOI: 10.3171/2015.9.JNS15754
- Nanda A, Bir SC, Maiti TK, Konar SK, Missios S, Guthikonda B. Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma. J Neurosurg. 2017;126(1):201–11. DOI: 10.3171/2016.1.JNS151842